Table 3.
Human Subjects Sub-Group Results on Phage Therapy for Urinary Tract Infections
| Organism | Percent (specified) | |||
|---|---|---|---|---|
| Gram negative (%) | 88.90 | |||
| Gram positive (%) | 3.40 | |||
| Gram negative and Gram positive (%) | 7.60 |
| Therapy | Total | Percent | ||
|---|---|---|---|---|
| |
Phage alone |
557 |
39.12 |
|
| |
Phage+Abxa |
261 |
18.33 |
|
| |
Not specified |
606 |
42.56 |
|
| Total | 1424 |
| Route of administration | Total | Percent | ||
|---|---|---|---|---|
| |
PO |
343 |
23.92 |
|
| |
Parenteral |
11 |
0.77 |
|
| |
Intravesicular |
579 |
40.38 |
|
| |
Topical/rectal |
30 |
2.09 |
|
| |
Combination |
205 |
14.30 |
|
| |
Not specified |
266 |
18.55 |
|
| Total | 1434 | |||
| Efficacy | Total | Percent (specified) | Percent (total) | |
|---|---|---|---|---|
| |
Marked clinical improvement/cure |
741 |
78.91 |
51.10 |
| |
Clinical improvement |
145 |
15.44 |
10.00 |
| |
No clinical improvement |
53 |
5.64 |
3.66 |
| |
Clinical improvement not specified |
511 |
|
35.24 |
| |
Total when specified |
939 |
|
|
| |
Total |
1450 |
|
|
| |
Marked microbiologic improvement/eradication |
726 |
66.67 |
63.52 |
| |
Microbiological improvement |
149 |
13.68 |
13.04 |
| |
No microbiological improvement |
214 |
19.65 |
18.72 |
| |
Microbiological improvement not specified |
54 |
|
4.72 |
| |
Total when specified |
1089 |
|
|
| Total | 1143 |
| Safety | Percent (specified) | Percent (total) | ||
|---|---|---|---|---|
| |
No adverse events |
621 |
98.73 |
43.37 |
| |
Adverse events reported |
8 |
1.27 |
0.56 |
| |
Adverse events not specified |
803 |
|
56.08 |
| |
Total when specified |
629 |
|
|
| Total | 1432 |
Tabulated data enumerating results from human case reports, case series, and clinical trials throughout the review period (until November 17, 2022). See Supplementary Table S5 for data extraction sheet.
a
Abx can include vaccine or toxoid therapy.
PO, oral administration.